June 2015
Volume 56, Issue 7
Free
ARVO Annual Meeting Abstract  |   June 2015
Infliximab for the treatment of ocular cicatricial pemphigoid, a Preliminary Report
Author Affiliations & Notes
  • Joan Jean Lee
    Uveitis, Massachusetts Eye Research and Surgery Institution, Cambridge, MA
  • Charles Stephen Foster
    Uveitis, Massachusetts Eye Research and Surgery Institution, Cambridge, MA
    Ophthalmology, Harvard Medical School, Cambridge, MA
  • Footnotes
    Commercial Relationships Joan Lee, None; Charles Foster, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2015, Vol.56, 857. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Joan Jean Lee, Charles Stephen Foster; Infliximab for the treatment of ocular cicatricial pemphigoid, a Preliminary Report. Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):857.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: The purpose of this study is to evaluate the efficacy of anti-TNF drug, Infliximab, in ocular cicatricial pemphigoid.

Methods: Retrospective chart review of a specialty practice.

Results: Nine patients with the diagnosis of ocular cicatricial pemphigoid who were treated with infliximab infusion were identified. Age at diagnosis ranged from 29-88 years old, six were female and 3 were male, and all patients had stage 1-3 disease. The follow up following diagnosis ranged from 1 consultation visit to 111 months. The dosage of infliximab used ranged from 4.76mg/kg to 7.5mg/kg. Four patients achieved remission with Infliximab alone, 1 patient achieved remission with infliximab and one other immune-modulatory drug and the remaining 4 patients failed to achieve remission with Infliximab.

Conclusions: Ocular cicatricial pemphigoid (OCP) is an inflammatory condition that is potentially blinding. Immunosuppressive chemotherapy is required to control this disease. Several chemotherapy medications have been used successfully in the treatment of OCP. However, treatment resistance and side effects to medication may limit a patient’s options for treatment. Elevated levels of tumor necrosis factor alpha in the serum and conjunctiva have been previously documented in patients with OCP. We report a preliminary set of data that show some promise in the efficacy of infused infliximab at doses of 4.76-7.5mg/kg in ocular cicatricial pemphigoid.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×